Karin Jorga, PhD

Publications

2012 Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer L, Gupta M, Tang M, Allison D, Lu D, Zhang Y, Joshi A and Dresser M A Guide to Rational Dosing of Monoclonal Antibodies Clin Pharmacokinet 51 (2): 119-135, 2012

2011 Graham R, Lum B, Cheeti S, Jin J, Jorga K, Von Hoff D, Rudin CM, Reddy J, LowJ, Lo Russo PM. Pharmacokinetics of hedgehog pathway inhibitor GDC-0449 in patients with locally-advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding Clinical Cancer Research, 17; 2512-2520, 2011

2010 Snoeck E, Chanu P, Lavielle M, Jaqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N. A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure Clin Pharmacol Ther, 87(6); 706-7013, 2010

2009 Claret L, Girard P, Hoff P, Van Cutsem E, Zuideveld K, Jorga K, Fagerberg J, Bruno R. Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics Journal of Clinical Oncology 27; 4103-4108, 2009

2008 Snoeck E, Hadziyannis S, Puoti C, Swain M, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuszem S Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon alfa-2a (40KD) plus ribavirin Liver International, 28(1); 61-71, 2008

2007 Jauslin P. Silber H, Frey N, Gieschke R, Simonsson U, Jorga K, Karsson M. An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics The Journal of Clinical Pharmacology, 47, 1244-1255, 2007

Cosson V, Jorga K, Fuseau E Modelling of Metabolite Pharmacokinetics in a Large Pharmacokinetic Data Set: An Application In “Pharmacometrics. The Science of Quantitative Pharmacology. Ette EI, Williams PJ (eds) , John Wiley & Sons, Hoboken, New Jersey, 2007

2006 Wade J, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus British Journal of Clinical Pharmacology, 62, 710-714, 2006

Snoeck E, Wade J, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin British Journal of Clinical Pharmacology, 62, 699-709, 2006

1/5

Jones HM, Parrott N, Jorga K, Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clinical Pharmacokinetetics, 45(5), 511-542, 2006

Gueorguieva I, Aarons L, Ogungbenro K, Jorga K, Rodgers T, Rowland M. Optimal Design of Multivariate Response Pharmacokinetic Models Journal of Pharmacokinetics and Pharmacodynamics, 33(2), 97-124, 2006

2002 Coleman MD, Hadley S, Perris AD, Jorga K, Seydel JK Studies on the toxicity and efficacy of some ester analogues of dapsone in vitro using rat and human tissues Environment Toxicology and Pharmacology 12, 7-13, 2002

Grub S, Schwarzwald H, Kline M, Jorga K Pharmacokinetics of saquinavir in children during long-term treatment of HIV infection The Pediatrics Infectious Disease Journal 21, 712-713, 2002

Grub S, DeLora P, Lüdin E, Duff F, Fletscher C, Brundage R, Kline M, Calles N, Schwarzwald H, Jorga K Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection Clin Pharmacol Ther 71, 122-130, 2002

Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43, 201-207, 2002

2001 Buss N, Snell P, Bock J, Steimer JL, Hsu A, Jorga K Saquinavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) anti-retroviral therapy British Journal of Clinical Pharmacology 52, 255-264, 2001

Kline M, Brundage R, Fletcher C, Schwarzwald H, Calles N, Buss N, Snell P, DeLora P, Eason M, Jorga K, Craig C, Duff F Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr Infect Dis J 20, 666-71, 2001

Grub S, Bryson H, Goggin T, Lüdin E, Jorga K The interaction of saquinavir (soft gelatin capsules) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and HIV-infected patients Eur J Clin Pharmacol 57, 115-121, 2001

2000 Jorga KM and van Brummelen P Drug Development: Experiences with the COMT-Inhibitor Tolcapone for the Treatment of Parkinson's Disease MEDCHEM NEWS (Japanese), 10 (3), 2000

2/5

Jorga KM, Fotteler B, Modi M, Rabbia M Effect of tolcapone on the hemodynamic effects and tolerability of desipramine European Neurology, 44, 94-103, 2000.

Jorga K, Banken L, Fotteler B, Snell P, Steimer JL Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone Clinical Pharmacology and Therapeutics, 67, 610-620, 2000.

Jorga KM, Fotteler B, Gasser R, Banken L Lack of interaction between tolcapone and tolbutamide in healthy volunteers Journal of Clinical Pharmacology, 40, 544-551, 2000

Jorga KM, Davis TL, Kurth MC, Saint-Hilaire MH, LeWitt PA, Fotteler B, Zürcher G, Rabbia M. Clinical, pharmacokinetic and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated parkinsonian patients Clinical Neuropharmacology, 23, 98-105, 2000

Jorga K, Fotteler B, Banken L, Snell P, Steimer JL Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies British Journal of Clinical Pharmacology, 49, 39-48, 2000.

1999 Schneider E and Jorga K L-DOPA In “Neuro-Psychopharmaka”, Bd. 5, 2. Aufl. Riederer P./Laux G./ Pöldinger (Hrsg.), Springer-Verlag, Wien, 1999

Jorga KM, Fotteler B, Heizmann P, Gasser R Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O- methyltransferase British Journal of Clinical Pharmacology, 48, 513-520, 1999.

Jorga KM and Nicholl DJ COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/carbidopa (Sinemet) British Journal of Clinical Pharmacology, 48, 449-452, 1999.

Jorga K. L-DOPA Pharmakokinetik unter COMT-Hemmung. In: Pharmakotherapie der Parkinson-Krankheit. Oertel WH (Ed.). Roche Editiones, Basel, 31-42, 1999.

Gasser UE, Jorga K, Crevoisier C, Hovens SEL, van Giersbergen PLM COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide Eur. Neurol. 41, 206-211, 1999

Jorga KM, Larsen JP, Beiske A, Schleimer M, Fotteler B, Schmitt M, Moe B. The effect of tolcapone on the pharmacokinetics of benserazide European Journal of Neurology, 6, 211-219, 1999

3/5

1998 Jorga KM, Fotteler B, Heizmann P, Zürcher G. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson’s disease therapy European Journal of Clinical Pharmacology, 54, 443-447, 1998

Jorga KM, Kroodsma JM, Fotteler B, Heizmann P, Meyer J, Rasch MC, van Hattum J. The effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites Clinical Pharmacology and Therapeutics, 63, 646-54, 1998

Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken JW. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation Journal of Neurology, 245, 223-230, 1998.

Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology, 50 (Suppl 5), S29-S36, 1998

Jorga KM. COMT Inhibitors: Pharmacokinetic and Pharmacodynamic Comparisons. Clin. Neuropharmacol. 21 (Suppl. 1), S9-S16, 1998.

1997 Sedek G, Jorga KM, Burns R, Schmitt M. Leese P Effect of tolcapone on plasma levodopa levels after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol., 10, 531-541, 1997

Jorga KM, Sedek G, Fotteler B, Zuercher G, Nielsen T, Aitken JW. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. 62, 300-310, 1997.

Jorga K, Banken L, Fotteler B Prospective PK/PD Population Analysis in the Clinical Development of Tolcapone: A COMT Inhibitor for the Treatment of Parkinson’s Disease In “COST B1, medicine. European cooperation in the field of scientific and technical research. The population approach: measuring and managing variability in reponse, concentration and dose.” Aarons (ed.), Office for Official Publications of the European Communities (EUR 17611 EN), Luxemburg, 1997

Jorga K, Fotteler B, Schmitt M, Nielsen T, Zuercher G, Aitken JW. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur. Neurol. 38, 59-67, 1997

Jorga K. Pharmakologie der COMT-Hemmer. In: Parkinson-Krankheit - Entwicklungen in Diagnositik und Therapie. Fischer PA (Ed.). Roche Editiones, Basel, 239-257, 1997.

4/5

Dingemanse J, Wood N, Jorga KM, Kettler R. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Br. J. Clin. Pharmacol. 43, 41-47, 1997

1996 Dingemanse J, Jorga KM, Zuercher G, Fotteler B, Sedek G, Nielsen T and van Brummelen P. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol. 50, 47-55, 1996

Da Prada M, Jorga KM. Response to Garrido et al.: Side Effects of the Catechol-O-Methyl-Transferase Inhibitor Ro 40-7592 in Rabbits” Clin. Neuropharmacol. 19, 98-99, 1996

1995 Dingemanse J, Jorga KM, Zuercher G, Schmitt M, Sedek G, Da Prada M and van Brummelen P. Pharmacokinetic-Pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br. J. Clin. Pharmac. 40, 253-262, 1995

Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zuercher G, Da Prada M, and van Brummelen P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O- methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57, 508-517, 1995.

Jorga K, Leenders KL, Guenther I, Psylla M. COMT inhibition: Pharmacology of tolcapone and 6-[18F]-Fluoro-L-Dopa (FDOPA) PET results. In: PET for Drug Development and Evaluation. Comar D (Ed.). Kluwer Academic Publishers, The Netherlands, 189-195, 1995.

1994 Da Prada M, Zuercher G, Kettler R, Dingemanse J, Jorga KM, Dubuis R. Inhibiting MAO-B with lazabemide and COMT with tolcapone. In: Antiparkinson Therapy: 20 years of Madopar - new avenues. Poewe W, Lees A (Eds.). Roche Editiones, Basel, 93-111, 1994.

5/5